Can a steroid implant boost the effect of standard eye injections for hard-to-treat diabetic macular edema?

NCT ID NCT04411693

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This trial investigates whether adding a dexamethasone implant (Ozurdex) to standard aflibercept (Eylea) injections can better control diabetic macular edema that has not responded to anti-VEGF therapy alone. Adults with persistent retinal swelling will receive either the combination or continued aflibercept alone and be followed for six months. The study measures changes in retinal thickness, visual acuity, and the number of injections needed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a dexamethasone implant (Ozurdex) added to aflibercept (Eylea) injections
What this could lead to
If it works, this combination approach could offer a more effective treatment option for people with diabetic macular edema that does not improve with standard anti-VEGF therapy alone.
What could go wrong
This is a small, early-phase trial with only 23 participants, so results may not apply broadly. Adding a steroid implant carries risks such as increased eye pressure or cataract formation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Retina Consultants of Houston

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.